2018 Volume 58 Issue 7 Pages 959-963
Objective. A small proportion of metastases are oligometastases, so a clear definition has yet to be established. Local consolidative therapy might be effective for patients with oligometastases; however, treatment analyses are insufficient. We reviewed the clinical outcomes of patients with non-small cell lung cancer (NSCLC) with oligometastases in our institution. Methods. We conducted a retrospective analysis of data for 10 patients with oligometastases among 525 patients who were diagnosed with stage IV NSCLC from April 2003 to September 2017. Results. The patient characteristics were as follows: male/female, 7/3; age, 38-72 years (median 65 years); histology, adenocarcinoma/NSCLC/large cell carcinoma/giant cell carcinoma = 6/2/1/1; gene mutations, EGFR/ALK/negative = 1/1/8; TNM classification (7th edition), T1/T2/T3 at 4/4/2; metastatic organ, brain/small intestine/adrenal gland/bone/liver/axillary lymph node at 4/2/1/1/1/1; number of metastases, 1/2/3 at 9/0/1; and performance status, 0/1/2 at 9/1/0. The following local treatments were performed in 8 patients: surgery/radiotherapy of the primary tumor and metastases/surgery and radiotherapy of metastases/radiotherapy of metastases in 4/1/1/2. Chemotherapy was performed for 8 patients. The median survival time (MST) was 35.7 months (9-55 months) for all 10 patients, 24.1 months (9-36 months) for those who were gene-mutation-negative, and 35 and 55 months for those who were EGFR- and ALK-positive, respectively. Conclusion. In our patients with oligometastases, local treatments for the primary tumor or metastases were performed in many cases, and the prognosis was relatively good.
